David J. Vocadlo received his B.Sc. in combined Chemistry and Biochemistry from the University of British Columbia in 1994. After working with D. Kilburn and R.A.J. Warren in the Michael Smith Laboratories (1994-1996) he returned to complete his Ph.D. in Bioorganic Chemistry with S.G. Withers at the University of British Columbia in 2002. As a Canadian Institutes of Health Research (CIHR) Postdoctoral Fellow, Dr. Vocadlo worked with C.R. Bertozzi at the University of California at Berkeley in the Departments of Chemistry and Molecular and Cell Biology (2002–2003). In 2004 he moved to the Department of Chemistry at Simon Fraser University (SFU) taking the role of Assistant Professor. He was promoted to Associate (2008) and Full Professor (2011) and is currently a Tier I Canada Research Chair in Chemical Glycobiology and Professor, jointly appointed in the Departments of Chemistry and Molecular Biology & Biochemistry. He leads the Laboratory for Chemical Glycobiology, which is focused on developing new glycomics tools and exploiting these in cellular and in vivo systems to better understand the roles of glycoconjugates in health and disease. Over several years, the group has developed a particular focus on the O-GlcNAc protein modification of nuclear and cytoplasmic proteins, which has emerged to be recognized as playing critical regulatory roles in humans. Based on research from his laboratory at SFU Dr. Vocadlo co-founded the biotechnology company Alectos Therapeutics. Dr. Vocadlo has published over 100 papers and his research team has been recognized by several awards including an EWR Steacie Memorial Fellowship, the Boehringer Ingelheim and Teva Canada Awards from the Canadian Society for Chemistry (CSC), and the Horace Isbell Award of the American Chemical Society (ACS). Dr. Vocadlo was recognized as one of Canada’s Top 40 Under 40 and was recently honoured as a member of the Royal Society of Canada, College of New Scholars.
- NEWS & EVENTS
- CORE SERVICES